nanosymposium - Society for Neuroscience

11:00 H49 346.8 Opioid agonists and antagonists alter
toll-like receptor-4 (TLR4) signaling. C. W. STEVENS*; S.
ARAVIND; R. L. DAVIS. OSU-Center For Hlth. Sci.
8:00 H50 346.9 • Reactive gliosis and invasion of activated
microglia, in a animal model of Experimental Autoimmune
Glaucoma. S. C. JOACHIM*; O. W. GRAMLICH; V. D. STAHL;
P. F. GOTTSCHLING; C. CUNY; N. PFEIFFER; F. H. GRUS.
Exptl. Ophthalmology.
9:00 H51 346.10 GABA is synthesized by astrocytes
at comparable levels to inhibitory neurons and has an
antiinflammatory effect on astrocytes and microglia. P. L.
MCGEER; E. G. MCGEER*; M. LEE; C. SCHWAB. Univ.
British Columbia.
10:00 H52 346.11 STAT3 inhibitors reduce human astrocytic
neurotoxicity. S. HASHIOKA*; A. KLEGERIS; P. L. MCGEER.
Univ. British Columbia, Univ. British Columbia Okanagan.
11:00 H53 346.12 Intracellular Ca 2+ dynamics underlying
ATP-induced TNFα release in MG5 microglial cells. S.
TSUNO; M. IKEDA; T. YOSHIOKA; T. SUGIYAMA*. Grad.
Sch. of Sci. and Engineering, Univ. of Toyama, Ctr. of
Excellent for Envrn. Medicine, Grad. Inst. of Med. Sciences,
Kaohsiung Med. Univ., Olympus Corp.
8:00 H54 346.13 Involvement of superoxide anion in the
induction of TNFα in microglia. K. NAKAJIMA*; Y. YOSHINO;
Y. TOHYAMA; S. KOHSAKA. Soka Univ., Natl. Inst. of
Neurosci.
9:00 H55 346.14 Prostaglandin modulates the TLR3induced
cytokine expression in human astroglioma CRT-MG
cells. J. SEO; K. LEE; C. PARK; S. JO; S. OH; K. PARK; J.
KIM; S. LEE; S. CHOI*. Seoul Natl. Univ., Kangwon Natl. Univ.
10:00 H56 346.15 Microglial peroxiredoxin V acts as an
inducible anti-inflammatory antioxidant through cooperation
with redox signaling cascades. D. LEE*; H. CHOI; S. KIM.
Kyungpook Natl. Univ., Natl. Primate Res. Center, Korea Res.
Inst. of Biosci. and Biotech. (KRIBB).
11:00 H57 346.16 • Trigeminal satellite cells and cortical
astrocytes express functional calcitonin gene-related peptide
receptor, whose activation enhances glial responses to
interleukin-1β. A. DE CORATO; L. LISI; A. CAPUANO; G.
TRINGALI; P. NAVARRA; C. DELLO RUSSO*. Univ. Cattolica
S.Cuore.
8:00 H58 346.17 Expression of signaling molecules and
receptors implicated in central sensitization is increased
by calcitonin gene-related peptide in cultured astrocytes
and microglia. J. STRIDER; C. V. VAUSE*; P. L. DURHAM.
Missouri State Univ.
POSTER
347. Tau: Role of Aggregated and Soluble Tau in Animal
Models
Theme C: Disorders of the Nervous System
Mon. 8:00 AM — San Diego Convention Center, Halls B-H
8:00 H59 347.1 A novel transgenic model with humanized
splicing of Tau Exon 10. A. GUMUCIO*; L. LANNFELT; L. N.
G. NILSSON. Rudbeck Laboratory, Publ. Hlth. and Caring
Sciences, Uppsala Univ.
9:00 H60 347.2 Biochemical characterization of protein
degradation pathways in a transgenic mouse model of Tau
pathology (THY-Tau22). M. HAMDANE*; J. DESMERCIÈRES;
C. LAURENT; S. BURNOUF; L. TROQUIER; A.
LEBOUCHER; D. DEMEYER; S. BECQUE; M. E.
GROSJEAN; R. CAILLIEREZ; I. BRION; F. FERNANDEZ-
GOMEZ; N. SERGEANT; D. BLUM; L. BUEE. INSERM U837,
Alzheimer & Tauopathies, USDL, Faculte De Medecine-Pole
Recherche, Univ. Lille Nord de France, JParc, IMPRT, CHU-
Lille.
10:00 H61 347.3 Impairment of BDNF-mediated
hippocampal synaptic facilitation in a transgenic model
of Alzheimer’s disease-like Tau pathology. D. BLUM*; S.
BURNOUF; A. MARTIRE; K. BELARBI; C. LAURENT; A.
MUHR-TAILLEUX; A. VAN DER JEUGD; A. LEBOUCHER;
F. FERNANDEZ-GOMEZ; L. TROQUIER; M. GROSJEAN;
D. DEMEYER; J. BRION; A. BUISSON; R. D’HOOGE; N.
SERGEANT; S. HUMEZ; M. HAMDANE; P. POPOLI; L.
BUÉE. Inserm U837, ISS, Inserm U1011, Katholieke Univ.
Leuven, ULB, Univ. de Caen Basse-Normandie.
11:00 H62 347.4 In vivo microdialysis assessment of brain
interstitial fluid tau levels. K. YAMADA*; J. R. CIRRITO; L. I.
BINDER; V. M. LEE; D. M. HOLTZMAN. Washington Univ.,
Northwestern Univ., Chicago, Univ. of Pennsylvania.
8:00 H63 347.5 • Dimebon improves spatial learning and
reduces phospho-Tau (Thr231)/total Tau ratio in TAU441
transgenic mice. A. A. PROTTER*; M. GIORGETTI; M.
MITROVIC; S. DULLER; R. RABL; B. HUTTER-PAIER.
Medivation, JSW Life Sci.
9:00 H64 347.6 • Analysis of gene expression in the
hippocampal subfields of Tg4510 and CAMKIIα-tTA
transgenic mice. P. D. WES*; A. EASTON; M. A. SEAGER; N.
X. BARREZUETA; C. BOURIN; J. HOGAN; A. TRUONG; A.
HE; D. BARTON; A. M. CACACE. Bristol-Myers Squibb.
10:00 H65 347.7 • Imbalanced expression of tau and
tubulin may be a determinant of the tauopathy cascade. T.
MIYASAKA*; Y. SHINZAKI; S. YOSHIMURA; S. YOSHINA;
E. KAGE-NAKADAI; S. MITANI; Y. IHARA. Doshisha Univ.,
Tokyo Women’s Med. Univ. Sch. of Medicine, Dept. of Physiol.
11:00 H66 347.8 Factors responsible for neurofibrillary
tangle formation and neuronal cell loss in tauopathy brains.
T. KAWARABAYASHI*; Y. WAKASAYA; M. WATANABE; Y.
YAMAMOTO-WATANABE; A. TAKAMURA; E. MATSUBARA;
M. SHOJI. Hirosaki Univ. Grad. Sch. of Med.
8:00 H67 347.9 Role of glucocorticoids in the development
of neuropathology in mouse models of both Alzheimer’s
disease and related tauopathies. J. C. CARROLL*; M. IBA; J.
Q. TROJANOWSKI; V. M. LEE. Univ. of Pennsylvania.
9:00 H68 347.10 Regulation of tau aggregates via
autophagy. W. YU*; H. Y. F. FIGUEROA; M. J. HERMAN; K.
E. K. DUFF. Columbia Univ., Res. Fndn. for Mental Hyg.
10:00 H69 347.11 Modulation of tau oligomers by passive
vaccination. D. L. CASTILLO*; C. LASAGNA-REEVES; M.
J. GUERRERO-MUNOZ; D. M. ESTES; A. BARRETT; K.
DINELEY; G. R. JACKSON; R. KAYED. UTMB.
11:00 H70 347.12 Loss of tau protects against APP
intracellular domain (AICD)-induced Alzheimer’s pathological
features. K. GHOSAL*; Q. FAN; H. N. DAWSON; S. W.
PIMPLIKAR. Cleveland Clinic, LRI, Duke Univ.
8:00 I1 347.13 Endogenous tau reduction ameliorates
Aβ-induced impairments in axonal transport. K. A. VOSSEL;
K. ZHANG; X. WANG; G. YU; K. HO; B. CUI; L. MUCKE*.
Gladstone Inst. of Neurolog. Dis., Stanford Univ., Univ. Calif
San Francisco.
22 | Society for Neuroscience • Indicated a real or perceived conflict of interest, see page 157 for details.
� Indicates a high school or undergraduate student presenter.